Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094700 | 0.90 | POLB (0.33) | PIK3CDPIK3CAPIK3CBPIK3CGPOLB | |
| SCHEMBL4088762 | 0.90 | PIK3CD (0.34) | PIK3CDPIK3CAPIK3CBPIK3CGSTING1 | |
| SCHEMBL4089531 | 0.89 | MIF (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL4089067 | 0.87 | NPC1 (0.34) | RORCMAPTTP53MEN1POLB | |
| SCHEMBL2952896 | 0.85 | MIF (0.34) | MAPTTP53MEN1POLBKMT2A | |
| SCHEMBL4621029 | 0.83 | RORC (0.38) | RORCMAPTTP53MEN1KMT2A | |
| SCHEMBL13199844 | 0.81 | CASP3 (0.33) | MAPTSTING1NPC1ALDH1A1RAB9A | |
| SCHEMBL4085450 | 0.80 | KDM4E (0.36) | MAPTTP53MEN1POLBKMT2A | |
| SCHEMBL4082600 | 0.80 | EGFR (0.38) | MAPTMEN1POLBKMT2A | |
| SCHEMBL13199840 | 0.79 | MIF (0.42) | MAPTTP53MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | MIF, CCL2, MSR1 | PIK3CD 4726/4885PIK3CA 4735/4885PIK3CB 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.